Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy

12Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Objective: In women with preeclampsia (PE), the serum concentration of the growth factor angiopoietin-2 (Ang-2) is significantly lower than in unaffected controls. The objective of this study is to determine if the decrease in serum Ang-2 is evident from the first trimester of pregnancy before the clinical onset of PE. Methods: Serum Ang-2 and uterine artery pulsatility index (PI) were measured at 11 to 13 weeks in 126 pregnancies that subsequently developed PE, 88 cases that developed gestational hypertension (GH) and 214 unaffected controls. Results: Maternal serum Ang-2 in the PE group [0.96 multiple of the median (MoM)] and in GH (1.12 MoM) was not significantly different from the unaffected group (1.07 MoM). Uterine artery PI was significantly higher in the PE group (1.32 MoM) but not in GH (1.11 MoM) compared to the unaffected group (1.05 MoM). Conclusion: In pregnancies that develop PE there is Doppler evidence of impaired placentation from the first trimester of pregnancy. However, the impaired placentation is not reflected in altered maternal serum levels of Ang-2. Copyright © 2009 John Wiley & Sons, Ltd.

Cite

CITATION STYLE

APA

Akolekar, R., Casagrandi, D., Skyfta, E., Ahmed, A. A., & Nicolaides, K. H. (2009). Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenatal Diagnosis, 29(9), 847–851. https://doi.org/10.1002/pd.2307

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free